These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 10367177)

  • 1. Present and future of 5-HT receptor agonists as antimigraine drugs.
    Pauwels PJ; John GW
    Clin Neuropharmacol; 1999; 22(3):123-36. PubMed ID: 10367177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
    Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
    Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of more and less lipophilic serotonin (5HT1B/1D) agonists in a model of trigeminovascular nociception in cat.
    Hoskin KL; Goadsby PJ
    Exp Neurol; 1998 Mar; 150(1):45-51. PubMed ID: 9514827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
    Peroutka SJ
    Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine.
    John GW; Pauwels PJ; Perez M; Halazy S; Le Grand B; Verscheure Y; Valentin JP; Palmier C; Wurch T; Chopin P; Marien M; Kleven MS; Koek W; Assie MB; Carilla-Durand E; Tarayre JP; Colpaert FC
    J Pharmacol Exp Ther; 1999 Jul; 290(1):83-95. PubMed ID: 10381763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
    Leysen JE; Gommeren W; Heylen L; Luyten WH; Van de Weyer I; Vanhoenacker P; Haegeman G; Schotte A; Van Gompel P; Wouters R; Lesage AS
    Mol Pharmacol; 1996 Dec; 50(6):1567-80. PubMed ID: 8967979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.
    Lynch JJ; Shen YT; Pittman TJ; Anderson KD; Koblan KS; Gould RJ; Regan CP; Kane SA
    Eur J Pharmacol; 2009 Nov; 623(1-3):96-102. PubMed ID: 19766109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
    Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
    J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
    Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
    Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine: pathophysiology, pharmacology, treatment and future trends.
    Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
    Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.
    Cohen ML; Schenck K
    J Pharmacol Exp Ther; 1999 Sep; 290(3):935-9. PubMed ID: 10454462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of agonists of serotonin receptor 5HT1B/D in pathogenesis and treatment of migraine attacks].
    Stepień A
    Pol Merkur Lekarski; 1999 Jun; 6(36):341-3. PubMed ID: 10481551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
    Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
    Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eletriptan.
    Sandrini G; Perrotta A; Tassorelli C; Nappi G
    Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1587-98. PubMed ID: 19929447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phe-124-Cys and A-161T variants of the human 5-HT1B receptor gene are not major determinants of the clinical response to sumatriptan.
    Mehrotra S; Vanmolkot KR; Frants RR; van den Maagdenberg AM; Ferrari MD; MaassenVanDenBrink A
    Headache; 2007 May; 47(5):711-6. PubMed ID: 17501853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
    Peroutka SJ
    Neurology; 1993 Jun; 43(6 Suppl 3):S34-8. PubMed ID: 8389009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the 5-HT
    Huang PC; Yang FC; Chang CM; Yang CP
    Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels.
    Bouchelet I; Cohen Z; Case B; Séguéla P; Hamel E
    Mol Pharmacol; 1996 Aug; 50(2):219-23. PubMed ID: 8700126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
    Villalón CM; VanDenBrink AM
    Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.